Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.680
Bid (Size) 8.680 (100)
Ask (Size) 8.800 (114)
Prev. Close 8.680
Today's Range 8.680 - 8.680
52wk Range 4.620 - 11.44
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sage (SAGE) Q2 Revenue Jumps 264%
Via The Motley Fool
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to... 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+50.2%
+50.2%
1 Month
-4.4%
-4.4%
3 Month
+16.0%
+16.0%
6 Month
+18.1%
+18.1%
1 Year
-20.7%
-20.7%

More News

Read More
Sage Therapeutics Announces Second Quarter 2025 Financial Results
From Sage Therapeutics, Inc.
Via Business Wire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
From Kahn Swick & Foti, LLC
Via Business Wire
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Via FinancialNewsMedia
Topics Death
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
From Phathom Pharmaceuticals
Via GlobeNewswire
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Via Stocktwits
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
From Kahn Swick & Foti, LLC
Via Business Wire
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
Via Benzinga
Topics Government
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Via Benzinga
Topics Stocks
Monday's session: top gainers and losers
Via Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is Sage Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sage Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sage Therapeutics, Inc. - Common Stock trade on?
Sage Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sage Therapeutics, Inc. - Common Stock?
The ticker symbol for Sage Therapeutics, Inc. - Common Stock is SAGE on the Nasdaq Stock Market
What is the current price of Sage Therapeutics, Inc. - Common Stock?
The current price of Sage Therapeutics, Inc. - Common Stock is 8.680
When was Sage Therapeutics, Inc. - Common Stock last traded?
The last trade of Sage Therapeutics, Inc. - Common Stock was at 07/30/25 04:00 PM ET
What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?
The market capitalization of Sage Therapeutics, Inc. - Common Stock is 518.74M
How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?
Sage Therapeutics, Inc. - Common Stock has 519M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.